FDA data Registry peer set 1 peer

Alternatives to bictegravir/emtricitabine/tenofovir

1 same-class SPL records vs bictegravir/emtricitabine/tenofovir - uses, FAERS reaction fields, and OTC/Rx flags from public FDA sources.

View bictegravir/emtricitabine/tenofovir → All alternatives

Brand: Biktarvy

Integrase Inhibitor / NRTI Combination Prescription 1 alternative found

About bictegravir/emtricitabine/tenofovir

Biktarvy is a complete HIV-1 treatment for adults and children who weigh at least 31 pounds. It combines three medicines into one tablet to help control the virus.

Used for: Biktarvy treats Human Immunodeficiency Virus type 1 (HIV-1) in adults and children weighing at least 31 pounds. It can be used if you have never taken HIV medicine before. It can also replace your current HIV medicine if your virus is under control and you have no resistance to Biktarvy's components.

View full bictegravir/emtricitabine/tenofovir profile →

1 Integrase Inhibitor / NRTI Combination peers (wide set)

dolutegravir/lamivudine

Rx

Dovato

Dovato is used to treat HIV-1 infection in adults and adolescents (12 years and older, weighing at least 55 pounds). It can be used if you have never taken HIV-1 medicines before. It can also be used to replace your current HIV-1 medicines if your virus is under control (HIV-1 RNA less than 50 copies/mL) and you have not had treatment failure or resistance to the medicines in Dovato.

Compare bictegravir/emtricitabine/tenofovir vs dolutegravir/lamivudine side-by-side →

bictegravir/emtricitabine/tenofovir peer mix vs class inventory

Peer mix

0 OTC and 1 Rx SPL records in this peer set (1 total). Class inventory for Integrase Inhibitor / NRTI Combination: 2 drugs.

Frequently Asked Questions

What same-class SPL records sit beside bictegravir/emtricitabine/tenofovir? ▼
This registry lists 1 Integrase Inhibitor / NRTI Combination medication records beside bictegravir/emtricitabine/tenofovir, including dolutegravir/lamivudine. Grouping is therapeutic-class indexing from openFDA/SPL, not a product recommendation.

Reading a wide Integrase Inhibitor / NRTI Combination peer set (1 records)

bictegravir/emtricitabine/tenofovir (Biktarvy) sits in a wide Integrase Inhibitor / NRTI Combination peer set (1 of 1 class peers shown). Labeled indication field for bictegravir/emtricitabine/tenofovir: Biktarvy treats Human Immunodeficiency Virus type 1 (HIV-1) in adults and children weighing at least 31 pounds.

FAERS top-reaction fields are thin or absent for bictegravir/emtricitabine/tenofovir in this extract; peer cards still expose SPL indication and OTC/Rx flags.

Registry note: Therapeutic-class peer lists are registry indexes, not prescribing advice. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.

Full bictegravir/emtricitabine/tenofovir profile →

Field note for bictegravir/emtricitabine/tenofovir: see also the generic vs brand label guide when reading Biktarvy SPL strings.

Read our methodology - how this data is sourced, computed, and verified.